Updates are available Correction dated 2022-06-03
Click to view Correction: https://doi.org/10.1038/s41431-022-01130-w
-
Authors
Liu, Mandi
Smith, Christopher L.
Biko, David M.
Li, Dong https://orcid.org/0000-0002-2265-6727
Pinto, Erin
O’Connor, Nora
Skraban, Cara
Zackai, Elaine H. https://orcid.org/0000-0002-8002-893X
Hakonarson, Hakon
Dori, Yoav
Sheppard, Sarah E. https://orcid.org/0000-0003-3480-8123
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (TL1TR001880)
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development
Uplifting Athletes/Lymphangiomatosis and Gorham's Disease Alliance
- License Information
-
More Information
Article History
Received: 8 October 2021
Revised: 3 May 2022
Accepted: 10 May 2022
First Online: 24 May 2022
Change Date: 3 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41431-022-01130-w
Competing interests
: HH and The Children’s Hospital of Philadelphia are equity holders in Nobias Therapeutics Inc., developing MEK inhibitor therapy for complex lymphatic anomalies. Other authors declare no competing interests.
: The Children’s Hospital of Philadelphia Institutional Review Board approved a registry and biorepository study (PI YD). Informed consent was obtained from all participants as required by the IRB.
